Compare NPKI & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | TYRA |
|---|---|---|
| Founded | 1932 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.4M | 844.2M |
| IPO Year | N/A | 2021 |
| Metric | NPKI | TYRA |
|---|---|---|
| Price | $12.92 | $22.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.17 | ★ $31.20 |
| AVG Volume (30 Days) | ★ 766.9K | 462.3K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $259,372,000.00 | N/A |
| Revenue This Year | $21.14 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $34.16 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $4.76 | $6.42 |
| 52 Week High | $14.00 | $22.83 |
| Indicator | NPKI | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 72.42 |
| Support Level | $11.17 | $20.08 |
| Resistance Level | $12.62 | $22.83 |
| Average True Range (ATR) | 0.46 | 1.60 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 98.45 | 89.04 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.